The disclosure provides a method of treating myeloid leukemia, the method comprising administering a GHRH antagonist to mammalian subject in need thereof. The disclosure further provides use of a GHRH antagonist for treating myeloid leukemia or in the preparation of a medicament for treating myeloid leukemia. The disclosure also provides a GHRH antagonist for use in treating myeloid leukemia.

The disclosure provides a method of treating myeloid leukemia, the method comprising administering a GHRH antagonist to mammalian subject in need thereof. The disclosure further provides use of a GHRH antagonist for treating myeloid leukemia or in the preparation of a medicament for treating myeloid leukemia. The disclosure also provides a GHRH antagonist for use in treating myeloid leukemia.

The present disclosure provides methods for treating mild brain injury and other neurological disorders in a subject in need thereof, comprising administering to the subject an effective amount of a compound comprising a ghrelin or ghrelin variant.

The present disclosure provides methods for treating mild brain injury and other neurological disorders in a subject in need thereof, comprising administering to the subject an effective amount of a compound comprising a ghrelin or ghrelin variant.

The disclosure provides a method of obtaining a population of cardiomyogenic precursor cells. The method comprises (a) differentiating induced pluripotent stem cells (iPSCs) to iPSC-derived cardiac precursor cells; and (b) isolating cardiac precursor cells expressing mammalian growth hormone-releasing hormone receptor (GHRHR) to obtain a population of iPSC-derived cardiomyogenic precursor cells.

The disclosure provides a method of obtaining a population of cardiomyogenic precursor cells. The method comprises (a) differentiating induced pluripotent stem cells (iPSCs) to iPSC-derived cardiac precursor cells; and (b) isolating cardiac precursor cells expressing mammalian growth hormone-releasing hormone receptor (GHRHR) to obtain a population of iPSC-derived cardiomyogenic precursor cells.

The present disclosure relates to a composition for the release of the bioactive substance comprising: sucrose acetate isobutyrate dissolved in an ionic liquid and an additive selected from the list consisting of: chitin, silk fibroin, cellulose, alginate, chitosan, gellan gum, dextrin, collagen, guar gum, carregeenan, heparin, kefiran, or mixtures thereof. By taking advantage of the properties of an ionic liquid (IL), in particular 1-butyl-imidazolium acetate (BMIMAc), it was possible to achieve a good dissolution of SAIB, which combined with chitin and/or silk, natural polymers, allows the development of the structures with different shape and sizes.

The present disclosure relates to a composition for the release of the bioactive substance comprising: sucrose acetate isobutyrate dissolved in an ionic liquid and an additive selected from the list consisting of: chitin, silk fibroin, cellulose, alginate, chitosan, gellan gum, dextrin, collagen, guar gum, carregeenan, heparin, kefiran, or mixtures thereof. By taking advantage of the properties of an ionic liquid (IL), in particular 1-butyl-imidazolium acetate (BMIMAc), it was possible to achieve a good dissolution of SAIB, which combined with chitin and/or silk, natural polymers, allows the development of the structures with different shape and sizes.

The present invention relates to a pharmaceutical composition including: a pharmaceutically effective amount of at least one peptide; and a pharmaceutically acceptable amount of a combination of: (a) at least one metal in form of any or a combination of a salt thereof and a complex thereof; and (b) at least one reducing agent, wherein, the at least one metal is selected from any or a combination of: vanadium, chromium and manganese, and wherein the combination of (a) at least one metal in form of any or a combination of a salt and a complex and (b) at least one reducing agent affords protection, at least in part, to the at least one peptide from proteolytic degradation upon ingestion thereof.

The present invention relates to a pharmaceutical composition including: a pharmaceutically effective amount of at least one peptide; and a pharmaceutically acceptable amount of a combination of: (a) at least one metal in form of any or a combination of a salt thereof and a complex thereof; and (b) at least one reducing agent, wherein, the at least one metal is selected from any or a combination of: vanadium, chromium and manganese, and wherein the combination of (a) at least one metal in form of any or a combination of a salt and a complex and (b) at least one reducing agent affords protection, at least in part, to the at least one peptide from proteolytic degradation upon ingestion thereof.